Impact of persistent bovine viral diarrhea virus infection on indicators of innate and adaptive immune function in holstein calves and cows / Impacto da infecção persistente pelo vírus da diarreia viral bovina sobre indicadores de função imunológica inata e adaptativa em bezerras e vacas holandesas

We evaluated some indicators of innate and humoral immune response in persistently infected (PI) Holstein calves and cows from 1 to 36 months of age matched with controls from the same herd. The effects were cataloged by grouping animals into the following age groups: <12 months, 13 to 24 months, and 25 to 36 months of age. Blood samples were collected once from each animal to measure total serum protein, haptoglobin, and neutralizing antibodies titers induced by respiratory virus vaccination. Total serum protein (g/dL) was lowest in PI calves younger until 24 months old, while haptoglobin concentration was higher in PI cattle. The serum neutralizing titers against BVDV and BRSV were lower in all PI calves and cattle than in controls. PI cattle have a high serum concentration of haptoglobin, and its possible dysregulated innate immune response appears to impact the efficacy of their adaptative immune responses, resulting in poor vaccine responsiveness.

O objetivo desta pesquisa foi avaliar alguns indicadores da resposta imune inata e humoral em bezerros a vacas persistentemente infectadas, entre um a 36 meses de idade, pareados com controles oriundos de um mesmo rebanho. As variáveis respostas foram avaliadas agrupando-se os animais nos seguintes grupos etários: < 12 meses, 13 a 24 meses, 25 a 36 meses de idade. Amostras sanguíneas foram coletadas para mensurar as concentrações séricas de proteína, haptoglobina e anticorpos neutralizantes induzidos pela vacinação contra as viroses respiratórias. Os teores de proteína sérica total (g/dL) foram menores nos animais persistentemente infectados (PI) jovens até 24 meses de idade, enquanto que a concentração de haptoglobina foi maior nos animais PI mais velhos (25 a 36 meses). Os títulos de anticorpos neutralizantes contra o BVDV e BRSV foi menor nos animais PIs independentemente da idade, comparado com o grupo controle. Os valores reduzidos ou nulos de anticorpos contra as viroses respiratórias, combinado com a evidência de resposta imune inata desregulada, contribui com a susceptibilidade dos animais PIs para as infecções secundárias.

Amazonian scorpions and scorpionism: integrating toxinological, clinical, and phylogenetic data to combat a human health crisis in the world's most diverse rainfores

Venom from Amazonian scorpions of the genus Tityus contains components capable of eliciting a distinct clinical, mostly neurological, syndrome. This contrasts with the mainly autonomic manifestations produced after envenomation by congeneric southern and northern South American species. Herein, we summarize Pan-Amazonian scorpionism by synthesizing available toxinological, clinical, and molecular data gathered from all affected areas in Amazonia, including Brazil, Ecuador, Colombia, Peru, Venezuela, and French Guiana. We searched multiple databases, as well as our own records, for reports of scorpion envenomations in Amazonia by confirmed Tityus spp., and compared the clinical manifestations. To help uncover clinical and venom relationships among problematic species, we explored phylogenetic relationships with a rate-calibrated analysis of mitochondrial COI data from available species. The possible existence of diversity gradients for venom toxic and immunogenic components despite the predicted strong phylogenetic association among species is underscored by discussed clinical and toxinological findings. A multicentric effort, involving all nations affected by this neglected disease, is urgently needed to offer alternatives for treating and understanding this pathology, including the preparation of neutralizing antibodies with a broad range of efficacy.(AU)

Immunogenicity in sheep of Uruguayan commercial vaccines against bovine alphaherpesvirus 1, 5 and bovine pestiviruses / Imunogenicidade em ovelhas de vacinas comerciais Uruguaias para alfaherpesvírus bovino 1, 5 e pestivírus de bovinos

The serological responses induced by four commercial inactivated Uruguayan vaccines against bovine alphaherpesviruses (BoHV)-1 and -5 and bovine pestiviruses (BVDV-1, BVDV-2, and HoBiPeV) were evaluated in sheep. Thirty-seven sheep were immunized twice (day 0 and 25) and their serum samples were tested at different intervals (days 0, 25, 40, 60, and 90) post-vaccination (PV). Among the four vaccines tested, only one (G4) could induce the production of moderate neutralizing antibody titers against BoHV-1 and -5 and BVDV-1 and -2. The G3 vaccine showed a neutralizing serological response against the bovine alphaherpesviruses only. The G1 and G2 vaccines produced extremely low levels of antibodies in a few vaccinated animals only (geometric mean titers (GMT) 2.2). Similar levels of immunological responses were induced by the G4 vaccine against BoHV-1 and -5, and titers of neutralizing antibodies induced in approximately 70% of the animals are known to confer protection (GMT > 8). For bovine pestiviruses, the vaccine stimulated response of G4 against BVDV-2 was higher compared to that against BVDV-1, and extremely low for HoBiPeV. The peak of neutralizing antibodies to BoHV-1 and BVDV-1 was observed on days 40 and 60 PV, respectively. Thereafter, a remarkably decrease in neutralizing antibody response was observed at day 90 PV. These results demonstrated that tested commercial Uruguayan vaccines did not induce a serological response of adequate magnitude and duration. Thus, it is important to periodically review formulations and compositions of commercial vaccines against bovine alphaherpesviruses and pestiviruses.(AU)

A resposta sorológica induzida por quatro vacinas comerciais uruguaias inativadas contra os alfaherpesvírus bovinos (BoHV-1 e -5) e pestivírus de bovinos (BVDV-1, BVDV-2 e HoBiPeV) foi avaliada em ovinos. Os animais foram imunizados duas vezes (dia 0 e dia 25) e o soro testado em diferentes intervalos (dias 0, 25, 40, 60 e 90) após a vacinação (PV). Dentre as quatro vacinas testadas, apenas uma (G4) apresentou títulos de anticorpos neutralizantes moderados para os BoHV-1 e -5, BVDV-1 e 2. A vacina G3 apresentou resposta somente para alfaherpesvírus bovinos. As vacinas G1 e G2 estimularam resposta somente em alguns animais vacinados. Para a vacina G4, observou-se que a resposta imunológica frente ao BoHV-1 e 5 foi semelhante e pelo menos 70% dos animais apresentaram níveis protetivos de anticorpos neutralizantes. Para os pestivírus bovinos, a vacina G4 estimulou resposta para o BVDV-2 mais elevada quando comparada com o BVDV-1, e quase que indetectável para HoBiPeV. O pico de anticorpos neutralizantes para o BoHV-1 foi observado no dia 40 PV e no dia 60 PV para o BVDV-1. Após isso, observou-se um decréscimo considerável na resposta de anticorpos neutralizantes. Os resultados demonstraram que vacinas comerciais uruguaias testadas não induziram resposta sorológica de magnitude e duração adequadas. Assim, ressalva-se a importância de rever periodicamente a formulação e composição das vacinas comerciais para alfaherpesvírus e pestivírus bovinos.(AU)

Positive effect of organic zinc supplementation on the persistence of anti-rabies neutralizing antibodies in healthy sheep / Efeito positivo da suplementação de zinco orgânico na persistência de anticorpos neutralizantes anti-rábicos em ovinos saudáveis

The main prophylactic tool to control rabies in herbivores is the systematic vaccination of susceptible animals. This study aimed to evaluate the positive effect of organic zinc (Zn) supplementation on the persistence of anti-rabies neutralizing antibodies in healthy sheep. A total of 36 Texel ewes were selected and randomly divided into 2 groups of 18 animals each. The treated group (TG) received organic Zn supplementation for 90 days, and after this period, 2 doses of rabies vaccine with a 30-day interval. The control group (CG) received the vaccine doses only and was not supplemented with organic Zn. Blood samples were collected before the first vaccination and 30, 60, and 90 days after vaccination, to determine the anti-rabies neutralizing antibody titer using the Rapid Fluorescent Focus Inhibition Test (RFFIT). The average values of anti-rabies serum-neutralizing antibodies 30 days after the first dose were 1.33 ± 0.62 IU mL-1 for the CG and 1.57 ± 0.80 IU mL-1 for the TG; 60 days after the second dose the average values were 7.60 ± 7.08 IU mL-1 and 12.97 ± 9.46 IU mL-1 for the CG and TG, respectively, with a significant difference between groups. The TG presented 100% vaccine coverage of the primary vaccination, whereas the CG presented 89.47% coverage. Oral supplementation with 75 mg organic Zn significantly increased the persistence of anti-rabies antibody titers in...

A principal ferramenta profilática para o controle da raiva em herbívoro é a vacinação sistemática de animais susceptíveis. A presente pesquisa teve como objetivo avaliar o efeito positivo da suplementação de zinco orgânico na persistência de anticorpos neutralizantes anti-rábicos em ovinos saudáveis. Foram selecionadas 36 ovelhas Texel, aleatoriamente divididos em dois grupos com 18 animais cada. O grupo tratado (GT) recebeu suplementação com zinco orgânico durante 90 dias, e, após este período, foram administradas 2 doses de vacina anti-rábica com intervalo entre elas de 30 dias. O grupo controle (GC) recebeu apenas as doses da vacina, e não foi suplementado com zinco. Amostras de sangue foram colhidas antes da primeira dose da vacina, e 30, 60 e 90 dias depois da vacinação, a fim de determinar o título de anticorpos neutralizantes anti-rábicos utilizando o teste rápido de inibição do foco fluorescente (RFFIT). As medias dos anticorpos anti-rábicos do soro, 30 dias após a primeira dose foi de 1,33 ± 0,62 IU mL-1 para o grupo controle, e 1,57 ± 0,80 IU mL-1 para o grupo tratado. 60 dias após a segunda dose, as medias foram de 7,60 ± 7,08 IU mL-1 e 12,97 ± 9,46 UI ml-1 no GC e GT, respectivamente, com significância entre os grupos. O GT apresentou 100% de cobertura vacinal na primeira dose, enquanto o GC apresentou 89,47%. A suplementação oral com 75 mg de zinco orgânico...

Positive effect of organic zinc supplementation on the persistence of anti-rabies neutralizing antibodies in healthy sheep / Efeito positivo da suplementação de zinco orgânico na persistência de anticorpos neutralizantes anti-rábicos em ovinos saudáveis

The main prophylactic tool to control rabies in herbivores is the systematic vaccination of susceptible animals. This study aimed to evaluate the positive effect of organic zinc (Zn) supplementation on the persistence of anti-rabies neutralizing antibodies in healthy sheep. A total of 36 Texel ewes were selected and randomly divided into 2 groups of 18 animals each. The treated group (TG) received organic Zn supplementation for 90 days, and after this period, 2 doses of rabies vaccine with a 30-day interval. The control group (CG) received the vaccine doses only and was not supplemented with organic Zn. Blood samples were collected before the first vaccination and 30, 60, and 90 days after vaccination, to determine the anti-rabies neutralizing antibody titer using the Rapid Fluorescent Focus Inhibition Test (RFFIT). The average values of anti-rabies serum-neutralizing antibodies 30 days after the first dose were 1.33 ± 0.62 IU mL-1 for the CG and 1.57 ± 0.80 IU mL-1 for the TG; 60 days after the second dose the average values were 7.60 ± 7.08 IU mL-1 and 12.97 ± 9.46 IU mL-1 for the CG and TG, respectively, with a significant difference between groups. The TG presented 100% vaccine coverage of the primary vaccination, whereas the CG presented 89.47% coverage. Oral supplementation with 75 mg organic Zn significantly increased the persistence of anti-rabies antibody titers in...(AU)

A principal ferramenta profilática para o controle da raiva em herbívoro é a vacinação sistemática de animais susceptíveis. A presente pesquisa teve como objetivo avaliar o efeito positivo da suplementação de zinco orgânico na persistência de anticorpos neutralizantes anti-rábicos em ovinos saudáveis. Foram selecionadas 36 ovelhas Texel, aleatoriamente divididos em dois grupos com 18 animais cada. O grupo tratado (GT) recebeu suplementação com zinco orgânico durante 90 dias, e, após este período, foram administradas 2 doses de vacina anti-rábica com intervalo entre elas de 30 dias. O grupo controle (GC) recebeu apenas as doses da vacina, e não foi suplementado com zinco. Amostras de sangue foram colhidas antes da primeira dose da vacina, e 30, 60 e 90 dias depois da vacinação, a fim de determinar o título de anticorpos neutralizantes anti-rábicos utilizando o teste rápido de inibição do foco fluorescente (RFFIT). As medias dos anticorpos anti-rábicos do soro, 30 dias após a primeira dose foi de 1,33 ± 0,62 IU mL-1 para o grupo controle, e 1,57 ± 0,80 IU mL-1 para o grupo tratado. 60 dias após a segunda dose, as medias foram de 7,60 ± 7,08 IU mL-1 e 12,97 ± 9,46 UI ml-1 no GC e GT, respectivamente, com significância entre os grupos. O GT apresentou 100% de cobertura vacinal na primeira dose, enquanto o GC apresentou 89,47%. A suplementação oral com 75 mg de zinco orgânico...(AU)

Antibodies against rabies virus in dogs with and without history of vaccination in Santa Maria - RS - Brazil / Anticorpos contra o vírus da raiva em cães com e sem histórico de vacinação em Santa Maria - RS - Brasil

The present study investigated the frequency and magnitude of neutralizing antibodies to rabies virus (RABV) in dogs with and without historic of vaccination in Santa Maria/RS. Group A included serum samples from 440 dogs with recent historic of vaccination against rabies, obtained during the 2015 rabies vaccination campaign. Group B included 300 serum samples from dogs submitted to the Veterinary Hospital of the Universidade Federal de Santa Maria in 2015, whose historic of rabies vaccination was unknown. Serum samples were submitted to the rapid fluorescent focus inhibition test (RFFIT) to detect neutralizing antibodies against RABV. In group A, 70.6% (310/440) of the samples had neutralizing antibody titers ≥0.5 international units per milliliter (IU mL-1), considered an indicative of protection against rabies by the World Health Organization. However, approximately 30% of the dogs did not contain antibodies in adequate levels. In group B, 42.3% (127/300) of the samples contained neutralizing antibody titers ≥0.5IU mL-1 and 57.7% (173/300) were negative or contained titers below of the value considered immunized. These results demonstrate that an important proportion of vaccinated dogs (~30%) did not develop adequate antibody levels, mainly those receiving a single vaccine dose. Serologic testing of animals with unknown historic of vaccination revealed relatively low vaccine coverage in the general dog population. Thus, reformulation of immunization strategies especially the recommendation of a boost vaccination 30 days after the primary dose and extension of vaccination campaigns are necessary to reach adequate levels and coverage of immunity against RABV in the canine population.(AU)

O presente estudo investigou a frequência e a magnitude dos anticorpos neutralizantes do vírus da raiva (RABV) em cães com e sem histórico de vacinação em Santa Maria/RS. O Grupo A incluiu amostras de soro de 440 cães com histórico recente de vacinação contra a raiva, obtidos durante a campanha de vacinação contra a raiva de 2015. O Grupo B incluiu 300 amostras de cães submetidos ao Hospital Veterinário da Universidade Federal de Santa Maria em 2015, cujo histórico de vacinação antirrábica era desconhecido. As amostras de soro foram submetidas ao teste rápido de inibição de focos fluorescentes para detecção de anticorpos neutralizantes do RABV. No grupo A, 70,6% (310/440) das amostras possuíam títulos de anticorpos neutralizantes ≥0,5 unidades internacionais por mililitro (UI mL-1), considerado um indicador de proteção contra a raiva pela Organização Mundial da Saúde. No entanto, aproximadamente 30% dos animais não continham anticorpos em níveis adequados. No grupo B, 42,3% (127/300) das amostras continham títulos de anticorpos neutralizantes ≥0,5UI mL-1e 57,7% (173/300) eram negativas ou continham títulos abaixo do valor considerado imunizado. Estes resultados demonstram que uma proporção importante de cães vacinados (~30%) não desenvolveu níveis adequados de anticorpos, principalmente aqueles que receberam uma única dose de vacina. O teste sorológico de animais com histórico de vacinação desconhecido revelou uma cobertura vacinal relativamente baixa na população geral de cães. Assim, a reformulação das estratégias de imunização especialmente a recomendação de uma vacinação de reforço 30 dias após a primeira dose e a extensão das campanhas de vacinação são necessárias para atingir níveis e cobertura adequados de imunidade contra o RABV na população canina.(AU)

Serological response to rabies virus induced by commercial vaccines in cattle / Resposta sorológica ao vírus da raiva induzida por vacinas comerciais em bovinos

The antibody response to rabies virus (RABV) induced by commercial vaccines in heifers was investigated. For this, 84 heifers were vaccinated twice (30 days interval) with each of four vaccines (G1 = 14 animals; G2 = 24; G3 = 22 and G4 = 24) and received a booster vaccination 360 days later. Serum samples collected at different intervals after vaccination and 30 days after booster were submitted to a virus neutralizing (VN) assay for RABV antibodies. Thirty days after the second vaccine dose, 92% of the immunized animals presented VN titers 0.5UI/mL (geometric medium titers [GMT] 1.7 to 3.8UI/mL). At the day of the booster (360 days post-vaccination); however, the percentage of animals harboring antibody titers 0.5UI/mL had dropped to 31% (0-80% of the animals, depending on the vaccine), resulting in lower GMT (0.1 to 0.6UI/mL). Booster vaccination at day 360 resulted in a detectable anamnestic response in all groups, resulting in 83% of animals (65 to 100%) harboring VN titers 0.5UI/mL thirty days later (GMT 0.6 to 4.3UI/mL). These results indicated that these vaccines were able to induce an adequate anti-RABV response in all animals after prime vaccination (and after booster as well). However, the titers decreased, reaching titers 0.5UI/mL in approximately 70% of animals within the interval before the recommended booster. Thus, booster vaccination for rabies in cattle using the current vaccines should be performed before the recommended one-year interval, as to maintain neutralizing antibodies levels in most vaccinated animals.

A resposta sorológica contra o vírus da raiva (RABV) induzida por vacinas comerciais foi investigada em bovinos. Para isso, 84 novilhas foram vacinadas duas vezes (30 dias de intervalo) com cada vacina (G1 = 14 animais; G2 = 24; G3 = 22 e G4 = 24) e receberam uma vacinação de reforço 360 dias depois. Amostras de soro coletadas em diferentes momentos após a vacinação e após o reforço vacinal foram submetidas ao teste de vírus neutralização (VN) para detecção de anticorpos contra o RABV. Trinta dias após a segunda dose vacinal, 92% dos animais apresentaram títulos neutralizantes 0,5UI/mL (GMT 1,7 a 3,8UI/mL). Porém, no dia do reforço (360 dias pós-vacinação), a porcentagem de animais que ainda apresentava títulos 0,5UI/mL havia se reduzido a 31% dos animais (0 a 80%, dependendo da vacina), resultando em baixos TMGs (0,1 a 0,6UI/mL). A vacinação de reforço no dia 360 resultou em resposta anamnéstica em todos os grupos, resultando em 83% (65 a 100%) de animais com títulos VN 0,5UI/mL trinta dias após (GMT 0,6 a 4,3UI mL-1). Esses resultados indicam que as vacinas avaliadas induzem uma resposta adequada de anticorpos anti-RABV após a vacinação (e também após o reforço). No entanto, os títulos reduzem-se, atingindo níveis 0,5UI/mL em 70% dos animais durante o intervalo antes do reforço. Assim, vacinação de reforço contra a raiva em bovinos, utilizando-se as vacinas atuais, deve ser realizada em intervalo inferior a um ano, de forma a manter os níveis de anticorpos neutralizantes na maioria dos animais.

Seroprevalence of bovine adenovirus and enterovirus antibodies reveals different infection dynamics in cattle herds

Background: Bovine enterovirus (BEV) and bovine adenovirus (BAV) are widely distributed in cattle population, and are among possible causes of gastroenteritis and respiratory disease, respectively, although the infection is more often subclinical. BAV infection may be also related to conjunctivitis, and may lead to severe infections and death in immunosuppressive calves. BEV infections have been associated with disorders of respiratory and reproductive tracts, and diarrhea. There is little available information about BAV and BEV in Brazil; however the main of the present study was to investigate the presence of antibodies against these viruses in cattle from some counties of the Rio Grande do Sul (RS), Brazil. Material, Methods & Results: A total of 415 bovine serum samples collected in 2015 year to detect neutralizing antibodies against BEV and BAV by Virus neutralization (VN) assay were performed. The serum samples were gently provided from Setor de Virologia da Universidade Federal de Santa Maria (SV-UFSM). The samples came from bovine with a history or report of clinical cases of diarrhea, respiratory and reproducible disorders and/or abortion suggestive of Leucosis, Bovine Viral Diarrhea Virus (BVDV) and/or Bovine herpesvirus type 1 and 5 (BoHV-1 and 5) infections. The samples are originated as from dairy and beef herd cattle in the following regions from RS State: Southwest, Northeast, Northwest, West, Southeast, Midwest and Metropolitan regions; and were classified according to the origin, gender and age. The serum samples were tested against 100 TCID50/mL of (tissue cellular infection dose 50/mL) of previously characterized BEV and BAV-3 isolates. Serial dilution of the serum was performed in duplicate, starting at 1:5 up to > 1:640 for BEV and at 1:2 to > 1:256 for BAV in 96 wells plates. The serum and virus mixture was incubated in 37ºC for 4-6 h and then a suspension of CRIB cells was added to each well. [...]

Serological response to rabies virus induced by commercial vaccines in cattle / Resposta sorológica ao vírus da raiva induzida por vacinas comerciais em bovinos

The antibody response to rabies virus (RABV) induced by commercial vaccines in heifers was investigated. For this, 84 heifers were vaccinated twice (30 days interval) with each of four vaccines (G1 = 14 animals; G2 = 24; G3 = 22 and G4 = 24) and received a booster vaccination 360 days later. Serum samples collected at different intervals after vaccination and 30 days after booster were submitted to a virus neutralizing (VN) assay for RABV antibodies. Thirty days after the second vaccine dose, 92% of the immunized animals presented VN titers 0.5UI/mL (geometric medium titers [GMT] 1.7 to 3.8UI/mL). At the day of the booster (360 days post-vaccination); however, the percentage of animals harboring antibody titers 0.5UI/mL had dropped to 31% (0-80% of the animals, depending on the vaccine), resulting in lower GMT (0.1 to 0.6UI/mL). Booster vaccination at day 360 resulted in a detectable anamnestic response in all groups, resulting in 83% of animals (65 to 100%) harboring VN titers 0.5UI/mL thirty days later (GMT 0.6 to 4.3UI/mL). These results indicated that these vaccines were able to induce an adequate anti-RABV response in all animals after prime vaccination (and after booster as well). However, the titers decreased, reaching titers 0.5UI/mL in approximately 70% of animals within the interval before the recommended booster. Thus, booster vaccination for rabies in cattle using the current vaccines should be performed before the recommended one-year interval, as to maintain neutralizing antibodies levels in most vaccinated animals.(AU)

A resposta sorológica contra o vírus da raiva (RABV) induzida por vacinas comerciais foi investigada em bovinos. Para isso, 84 novilhas foram vacinadas duas vezes (30 dias de intervalo) com cada vacina (G1 = 14 animais; G2 = 24; G3 = 22 e G4 = 24) e receberam uma vacinação de reforço 360 dias depois. Amostras de soro coletadas em diferentes momentos após a vacinação e após o reforço vacinal foram submetidas ao teste de vírus neutralização (VN) para detecção de anticorpos contra o RABV. Trinta dias após a segunda dose vacinal, 92% dos animais apresentaram títulos neutralizantes 0,5UI/mL (GMT 1,7 a 3,8UI/mL). Porém, no dia do reforço (360 dias pós-vacinação), a porcentagem de animais que ainda apresentava títulos 0,5UI/mL havia se reduzido a 31% dos animais (0 a 80%, dependendo da vacina), resultando em baixos TMGs (0,1 a 0,6UI/mL). A vacinação de reforço no dia 360 resultou em resposta anamnéstica em todos os grupos, resultando em 83% (65 a 100%) de animais com títulos VN 0,5UI/mL trinta dias após (GMT 0,6 a 4,3UI mL-1). Esses resultados indicam que as vacinas avaliadas induzem uma resposta adequada de anticorpos anti-RABV após a vacinação (e também após o reforço). No entanto, os títulos reduzem-se, atingindo níveis 0,5UI/mL em 70% dos animais durante o intervalo antes do reforço. Assim, vacinação de reforço contra a raiva em bovinos, utilizando-se as vacinas atuais, deve ser realizada em intervalo inferior a um ano, de forma a manter os níveis de anticorpos neutralizantes na maioria dos animais.(AU)

Seroprevalence of bovine adenovirus and enterovirus antibodies reveals different infection dynamics in cattle herds

Background: Bovine enterovirus (BEV) and bovine adenovirus (BAV) are widely distributed in cattle population, and are among possible causes of gastroenteritis and respiratory disease, respectively, although the infection is more often subclinical. BAV infection may be also related to conjunctivitis, and may lead to severe infections and death in immunosuppressive calves. BEV infections have been associated with disorders of respiratory and reproductive tracts, and diarrhea. There is little available information about BAV and BEV in Brazil; however the main of the present study was to investigate the presence of antibodies against these viruses in cattle from some counties of the Rio Grande do Sul (RS), Brazil. Material, Methods & Results: A total of 415 bovine serum samples collected in 2015 year to detect neutralizing antibodies against BEV and BAV by Virus neutralization (VN) assay were performed. The serum samples were gently provided from Setor de Virologia da Universidade Federal de Santa Maria (SV-UFSM). The samples came from bovine with a history or report of clinical cases of diarrhea, respiratory and reproducible disorders and/or abortion suggestive of Leucosis, Bovine Viral Diarrhea Virus (BVDV) and/or Bovine herpesvirus type 1 and 5 (BoHV-1 and 5) infections. The samples are originated as from dairy and beef herd cattle in the following regions from RS State: Southwest, Northeast, Northwest, West, Southeast, Midwest and Metropolitan regions; and were classified according to the origin, gender and age. The serum samples were tested against 100 TCID50/mL of (tissue cellular infection dose 50/mL) of previously characterized BEV and BAV-3 isolates. Serial dilution of the serum was performed in duplicate, starting at 1:5 up to > 1:640 for BEV and at 1:2 to > 1:256 for BAV in 96 wells plates. The serum and virus mixture was incubated in 37ºC for 4-6 h and then a suspension of CRIB cells was added to each well. [...] (AU)

Immune response in holstein calves vaccinated at six months of age

Background: Calves are agammaglobulinemic and immature at birth and their immunological defense must be improved by colostrum, although, maternal antibodies decrease after two months of age and calves are susceptible to Bovine Respiratory Disease Complex (BRDC). Then, this research evaluated the immune response to BVDV and BoHV-1 in young calves to prevent BRDC.Materials, Methods & Results: Ten male Holstein calves were distributed in two groups with five animals on each: nonvaccinated VAC (-) and vaccinated VAC (+). Calves were vaccinated twice at 180 and 210 days of age. It was selected a commercial multivalent vaccine containing inactivated isolated of BVDV type-1 (strains 5960) and BVDV type-2 (strains 53637), and modified-live BoHV-1 (strains RLB103), with Quil A, cholesterol and Amphigen as adjuvant. The immune response (IR) was evaluated at 180 (T0), 210 (T1) and 240 (T2) days of life by serum neutralization (SN) and immunophenotyping. Specific antibodies to BVDV were detected in 40% (2/5) and 60% (3/5) of vaccinated calves at T1 and T2, respectively. Specific antibodies (Abs) to BoHV-1 were observed in 40% (2/5) at T1 and 100% (5/5) at T2 in the VAC (+) group. Titers of Abs to BoHV-1 increase from T0 to T2 (P = 0.034) in VAC (+). Moreover, geometric mean titer (GMT) to BoHV-1 in VAC (+) group was higher than VAC (-) after secondary IR in T2 (P = 0.006). The proportion of the markers T lymphocytes subpopulation (CD3+ , CD4+ , CD8+ and WC1+ ) and B lymphocytes (CD21+ ) were similar in the two experimental groups, while the expression of the CD25+ marker by gamma-delta (WC1+ ) was higher in VAC (+) at T1.Discussion: Low titers of circulating Abs could be observed just for BoHV-1 in the calves from VAC (-) at T0, probably due to remaining Abs from dams transferred by colostrum intake. This fact indicates the need of appropriate vaccination schedules to prevent the virosis in dairy heifers.[...]

Immune response in holstein calves vaccinated at six months of age

Background: Calves are agammaglobulinemic and immature at birth and their immunological defense must be improved by colostrum, although, maternal antibodies decrease after two months of age and calves are susceptible to Bovine Respiratory Disease Complex (BRDC). Then, this research evaluated the immune response to BVDV and BoHV-1 in young calves to prevent BRDC.Materials, Methods & Results: Ten male Holstein calves were distributed in two groups with five animals on each: nonvaccinated VAC (-) and vaccinated VAC (+). Calves were vaccinated twice at 180 and 210 days of age. It was selected a commercial multivalent vaccine containing inactivated isolated of BVDV type-1 (strains 5960) and BVDV type-2 (strains 53637), and modified-live BoHV-1 (strains RLB103), with Quil A, cholesterol and Amphigen as adjuvant. The immune response (IR) was evaluated at 180 (T0), 210 (T1) and 240 (T2) days of life by serum neutralization (SN) and immunophenotyping. Specific antibodies to BVDV were detected in 40% (2/5) and 60% (3/5) of vaccinated calves at T1 and T2, respectively. Specific antibodies (Abs) to BoHV-1 were observed in 40% (2/5) at T1 and 100% (5/5) at T2 in the VAC (+) group. Titers of Abs to BoHV-1 increase from T0 to T2 (P = 0.034) in VAC (+). Moreover, geometric mean titer (GMT) to BoHV-1 in VAC (+) group was higher than VAC (-) after secondary IR in T2 (P = 0.006). The proportion of the markers T lymphocytes subpopulation (CD3+ , CD4+ , CD8+ and WC1+ ) and B lymphocytes (CD21+ ) were similar in the two experimental groups, while the expression of the CD25+ marker by gamma-delta (WC1+ ) was higher in VAC (+) at T1.Discussion: Low titers of circulating Abs could be observed just for BoHV-1 in the calves from VAC (-) at T0, probably due to remaining Abs from dams transferred by colostrum intake. This fact indicates the need of appropriate vaccination schedules to prevent the virosis in dairy heifers.[...](AU)

Production of egg yolk antibody (IgY) against recombinant porcine epidemic diarrhea virus COE protein

Background: Porcine epidemic diarrhea (PED) is a highly contagious disease of pigs, and is characterized by a series ofclinical symptoms, such as severe diarrhea, vomiting and dehydration. Partial protective antigen gene (COE gene) of Sprotein possessing the main B cell epitope, is able to encode proteins with reactogenicity to induce the production of neutralizing antibodies. IgY was found to reduce the mortality in piglets after challenge exposures. Anti-COE IgY antibodyhas never been reported before, here it is described a method for the production of anti-COE IgY, which could be appliedin the treatment for the porcine epidemic diarrhea virus (PEDV) infection.Materials, Methods & Results: A PEDV strain was isolated from a clinical sample. The COE ORF (Open reading frame,ORF)was amplifi ed by PCR and iserted into the pMD18-T clone vector. The isolated was defi ned as Porcine epidemic diarrheavirus strain JS-HZ2012 subtype by sequencing, the clinical sample was defi ned as the nucleic acid sequence has a 99.5%homology with that of PEDV CV777 strain. And then the COE ORF was subcloned into pET-32a by T4 DNA ligase andintroduced into the E.coli Bal21 (DE3). COE protein was produced by the induction of the E.coli Bal21 containing pET32a-COE with isopropyl-β-D-1-thiogalactopyrannoside (IPTG). Expression of the recombinant COE protein (rCOE)fused with His-tag was analyzed by SDS-PAGE and detected by western-blotting using anti-His monoclonal antibody.The rCOE was purifi ed by Ni+ affi nity purifi cation chromatography under denature condition and dialyzed against PBS.The concentration of the rCOE was determined by BCA method. After immunnizing the chickens with rCOE , All animalhandling procedures were performed under veterinary supervision and following the recommendations of the local lawsand regulations on Animal Experimentation. Anti-COE IgY was isolated by chloroform extraction and...(AU)

Production of egg yolk antibody (IgY) against recombinant porcine epidemic diarrhea virus COE protein

Background: Porcine epidemic diarrhea (PED) is a highly contagious disease of pigs, and is characterized by a series ofclinical symptoms, such as severe diarrhea, vomiting and dehydration. Partial protective antigen gene (COE gene) of Sprotein possessing the main B cell epitope, is able to encode proteins with reactogenicity to induce the production of neutralizing antibodies. IgY was found to reduce the mortality in piglets after challenge exposures. Anti-COE IgY antibodyhas never been reported before, here it is described a method for the production of anti-COE IgY, which could be appliedin the treatment for the porcine epidemic diarrhea virus (PEDV) infection.Materials, Methods & Results: A PEDV strain was isolated from a clinical sample. The COE ORF (Open reading frame,ORF)was amplifi ed by PCR and iserted into the pMD18-T clone vector. The isolated was defi ned as Porcine epidemic diarrheavirus strain JS-HZ2012 subtype by sequencing, the clinical sample was defi ned as the nucleic acid sequence has a 99.5%homology with that of PEDV CV777 strain. And then the COE ORF was subcloned into pET-32a by T4 DNA ligase andintroduced into the E.coli Bal21 (DE3). COE protein was produced by the induction of the E.coli Bal21 containing pET32a-COE with isopropyl-β-D-1-thiogalactopyrannoside (IPTG). Expression of the recombinant COE protein (rCOE)fused with His-tag was analyzed by SDS-PAGE and detected by western-blotting using anti-His monoclonal antibody.The rCOE was purifi ed by Ni+ affi nity purifi cation chromatography under denature condition and dialyzed against PBS.The concentration of the rCOE was determined by BCA method. After immunnizing the chickens with rCOE , All animalhandling procedures were performed under veterinary supervision and following the recommendations of the local lawsand regulations on Animal Experimentation. Anti-COE IgY was isolated by chloroform extraction and...

Occurrence of neutralizing antibodies against BVDV-1 and BVDV-2 in cattle herds from Minas Gerais and São Paulo States, Brazil / Ocorrência de anticorpos neutralizantes contra o BVDV-1 e o BVDV-2 em rebanhos bovinos de Minas Gerais e São Paulo, Brasil

The occurrence of neutralizing antibodies against bovine viral diarrhea virus genotypes (BVDV-1 and BVDV-2) has been confirmed by virus neutralization test (VN) in samples of blood serum from 26 cattle herds which were not BVDV vaccinated, located in the states of Minas Gerais and São Paulo, Brazil. Ten blood samples were collected from each herd, five samples from 6 to 12-month-old calves and five samples from adult bovines. Of the total samples analyzed, 102 (39.2%) were reactive to BVDV, more specifically, 81 (31.1%) were reactive to BVDV-1 and BVDV-2, seven (2.7%) were reactive to BVDV-1 only and 14 (5.4%) were reactive to BVDV-2 only. Except for two herds, in all others at least one animal was detected reactive to BVDV, however, one of them was reactive to BVDV-2 only. In six herds, neutralizing antibodies were detected in blood serum from 6 to 12-month-old calves. Therefore, were indicative of recent BVDV infection and also suggested the likely presence of an infection source in the herd. The results showed the occurrence of neutralizing antibodies against BVDV genotypes in cattle herds located in the states analyzed, but these same results demonstrated the differences in the number of bovines reactive for BVDV-1 and BVDV-2, thus demonstrating the need to use strains from each genotype in VN tests for serological diagnosis of BVDV.

A ocorrência de anticorpos neutralizantes contra os genótipos do vírus da diarréia viral bovina (BVDV-1 e BVDV-2) foi determinada pelo teste de virusneutralização (VN) em amostras de soro sangüíneo provenientes de 26 rebanhos bovinos não vacinados contra o BVDV, localizados nos Estados de Minas Gerais e São Paulo, Brasil. Foram analisadas 10 amostras por rebanho, sendo cinco de bovinos adultos e cinco de bovinos com idade entre 6 e 12 meses. Do total de 260 amostras analisadas, 102 (39,2%) reagiram ao BVDV, das quais 81 (31,1%) foram reagentes tanto ao BVDV-1 quanto ao BVDV-2, sete (2,7%) reagiram apenas ao BVDV-1 e 14 (5,4%) reagiram apenas ao BVDV-2. Com exceção de dois rebanhos, nos demais foram detectados pelo menos um animal reagente ao BVDV, entretanto, foram detectados animais reagentes apenas ao BVDV-2 em um deles. Em seis rebanhos foram detectados anticorpos neutralizantes nos bovinos da faixa etária de 6 a 12 meses, sendo, portanto, indicativos da infecção recente pelo vírus e também sugestivos da provável presença da fonte de infecção no rebanho. Os dados obtidos mostraram a ocorrência de anticorpos neutralizantes contra os genótipos do BVDV em rebanhos bovinos localizados nos Estados analisados, mas os resultados apresentaram diferenças no número de bovinos reagentes ao BVDV-1 e ao BVDV-2, ressaltando assim a necessidade da utilização de estirpes de cada genótipo nos testes de VN para o diagnóstico sorológico do BVDV.

Suplementação de vacas leiteiras com homeopatia: células somáticas do leite, cortisol e imunidade / Supplementation of dairy cows with homeopathy: milk somatic cells, cortisol and immunity

Avaliou-se o efeito da suplementação de uma combinação homeopática sobre a contagem de células somáticas do leite (CCS), o teor sanguíneo de cortisol e a resposta de anticorpos neutralizantes antivírus da raiva de vacas leiteiras. Trinta e duas vacas Holandesas em lactação foram blocadas em pares e aleatoriamente alocadas a um de dois tratamentos por 63 dias, posterior a um período de padronização de 14 dias. A CCS mensurada no final da padronização ajustou os valores semanais de CCS no modelo de análise estatística. Os tratamentos foram: 150 gramas de uma combinação homeopática (Hypothalamus, 10-30; Colibacilinum, 10-30; Streptococus Beta Hemolyticum, 10-60; Streptococus Uberis, 10-60; Phytolacca, 10-60; Calcium Phosphoricum, 10-30; Natrum Muriaticum, 10-60; Urtica Urens, 10-30; Silicea Terra, 10-400) em veículo mineral, ou 150 gramas do mesmo veículo mineral (controle). A homeopatia tendeu a aumentar a CCS de 124 para 222 x1.000 células mL-1 (P=0,09) e a CCS linearizada (P=0,08). Não foram detectados efeitos de tratamento sobre a concentração sérica de cortisol após estresse induzido por aspiração percutânea do saco ventral do rúmen (P=0,59) ou sobre o título de anticorpos neutralizantes em resposta à vacinação antivírus da raiva (P=0,40). A suplementação com homeopatia tendeu a aumentar a CCS de vacas com baixa CCS.(AU)

The effect of supplementing a homeopathic combination on milk somatic cell count (SCC), blood cortisol content and the antibody response to rabies vaccination of dairy cows was evaluated. Thirty-two lactating Holstein cows were paired blocked and randomly assigned to one of two treatments for 63 days, following a 14-day standardization period. The SCC measured at the end of standardization period adjusted weekly SCC values in the statistical analysis model. Treatments were: 150 grams of a homeopathic combination (Hypothalamus, 10-30; Colibacilinum, 10-30; Streptococcus Beta Hemolyticum, 10-60, Streptococcus Uberis, 10-60; Phytolacca, 10-60; Calcium Phosphoricum, 10-30; Natrum Muriaticum, 10-60; Urtica Urens, 10-30, Silicea Terra, 10-400) in mineral vehicle, or 150 grams of the same mineral vehicle (Control). Homeopathy tended to increase SCC from 124 to 222 x1,000 cells mL-1 (P=0.09) and linear SCC (P=0.08). There were no detectable treatment effects upon serum cortisol concentration following stress induced by percutaneous aspiration of the ventral rumen (P=0.59) and upon serum antibody title in response to rabies vaccination (P=0.40). The supplementation with homeopathy tented to increase the SCC of low SCC cows.(AU)

Proteção fetal contra o vírus da diarréia viral bovina (BVDV) em vacas prenhes previamente imunizadas com uma vacina experimental atenuada / Fetal protection against bovine viral diarrhea virus (BVDV) in pregnant cows previously immunized with an experimental attenuated vaccine

Esse artigo relata a avaliação da resposta sorológica e proteção fetal conferida por uma vacina experimental contendo duas amostras atenuadas do vírus da diarréia viral bovina tipos 1 (BVDV-1) e 2 (BVDV-2). Vacas foram imunizadas com a vacina experimental (n=19) e juntamente com controles não-vacinadas (n=18) foram colocadas em cobertura e desafiadas, entre os dias 60 e 90 de gestação, pela inoculação intranasal de quatro amostras heterólogas de BVDV-1 e BVDV-2. A resposta sorológica foi avaliada por testes de soro-neutralização realizados a diferentes intervalos após a vacinação (dias 34, 78 e 138 pós-vacinação [pv]). A proteção fetal foi monitorada por exames ultra-sonográficos e clínicos realizados durante o restante da gestação; e pela pesquisa de vírus e anticorpos no sangue pré-colostral coletado dos fetos abortados e/ou dos bezerros recém nascidos. No dia do desafio (dia 138 pv), todas as vacas vacinadas apresentavam anticorpos neutralizantes em títulos altos contra o BVDV-1 (1.280- >10.240) e, com exceção de uma vaca (título 20), todas apresentavam títulos médios a altos contra o BVDV-2 (80-1.280). O monitoramento da gestação revelou que, dentre as 18 vacas não-vacinadas, apenas três (16,6 por cento) pariram bezerros saudáveis e livres de vírus. As 15 restantes (83,3 por cento) apresentaram indicativos de infecção fetal e/ou falhas reprodutivas. Sete dessas vacas (38,8 por cento) pariram bezerros positivos para o vírus, sendo que cinco eram saudáveis e sobreviveram (27,7 por cento); e dois apresentavam sinais de prematuridade ou fraqueza e morreram três e 15 dias após o nascimento, respectivamente. As oito vacas controle restantes (44,4 por cento) abortaram entre o dia 30 pós-desafio e às proximidades do parto, ou deram à luz bezerros prematuros, inviáveis ou natimortos. Por outro lado, 17 de 19 (89,4 por cento) vacas vacinadas deram à luz bezerros saudáveis e livres de vírus. Uma vaca vacinada abortou 130 dias pós-desafio, mas...(AU)

This paper reports the antibody response and fetal protection in pregnant cows conferred by an experimental vaccine containing two attenuated strains of bovine viral diarrhea virus (BVDV-1 and BVDV-2). Cows (n=19) were vaccinated twice, with a 34 days-interval, with the experimental vaccine and together with non-vaccinated controls (n=18), were mated and challenged between days 60 and 90 of gestation by intranasal inoculation of four heterologous BVDV-1 and BVDV-2 isolates. The antibody response was evaluated by serum-neutralization tests performed at different intervals after vaccination (days 34, 78 and 138 post-vaccination [pv]). Fetal protection was monitored by ultrassonographic and clinical examination of the dams and fetuses during the rest of gestation; and through virological and serological examination of pre-colostral blood obtained from aborted and/or recently born fetuses/calves. At the day of challenge (day 138 pv), all vaccinated cows had neutralizing antibodies in high titers against BVDV-1 (1,280->10,240), and with one exception (titer 20), presented moderate to high titers to BVDV-2 (80-1,280). At the end of the monitoring, only three out of 18 control cows (16.6 percent) delivered healthy, virus-free calves. Fifteen non-vaccinated cows (83.3 percent) presented signs of fetal infection and/or had reproductive losses. Seven of these cows (38.8 percent) delivered virus-positive calves; five were healthy and survived (27.7 percent); two were premature or weak and lasted three and 15 days, respectively. The other eight cows (44.4 percent) aborted between day 30 post-challenge and the parturition; or delivered premature or stillbirth calves. In contrast, 17 out of 19 (89.4 percent) vaccinated cows delivery virus-free, healthy calves. One vaccinated cow aborted around day 130 post-challenge, yet this fetus could not be examined for the presence of virus. Another cow delivered a virus-positive calf (5.2 percent). In summary...(AU)